BEIJING, Sept. 17, 2018 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider
of biopharmaceutical products in China, today announced that the U.S.
Department of Justice ("DOJ") has closed its investigation, with no
charges, into possible violations of the Foreign Corrupt Practices
Act related to allegations that certain Sinovac employees made
improper payments to Chinese government officials. The closing of
the DOJ investigation follows the SEC's termination of its related
investigation, which the Company announced on August 20, 2018. With the closure of the
DOJ's investigation, the Company is not aware of any pending U.S.
government investigations of the Company related to these matters.
Sinovac is committed to conducting business in compliance with all
applicable laws and cooperated fully with the DOJ. Sinovac will
continue in its mission of researching, developing, manufacturing
and commercializing vaccines that protect against human infectious
diseases.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical Company that
focuses on the research, development, manufacturing and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu), and
mumps. Healive, the hepatitis A vaccine manufactured by the Company
has passed the assessment under WHO Prequalification procedures in
2017. The EV71 vaccine, an innovative vaccine developed by Sinovac
against hand foot and mouth disease caused by EV71, was
commercialized in China in 2016.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. The
Company is developing a number of new products including a
Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to over 10 countries in Asia and South
America. For more information please refer to the Company's
website at www.sinovacbio.com.
Safe Harbor Statement
This announcement may include certain statements that are not
descriptions of historical facts, but are forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements.
Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from
those contained in any such statements.
Investor Contacts:
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR
Bill Zima
Tel: +1-646-308-1707
Email: william.zima@icrinc.com
Media Contact:
Abernathy MacGregor
Sheila Ennis
Tel: +1-415-745-3294
Email: sbe@abmac.com
China Media Contact:
ICR
Edmond Lococo
Tel: +86-10-6583-7510
Email: Edmond.Lococo@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/doj-closes-investigation-of-sinovac-300713560.html
SOURCE Sinovac Biotech Ltd.